MYO1

MYO1 is a preclinical **small molecule** drug candidate from **Myocea** being developed for **spinal muscular atrophy**. In Myocea's pipeline, it is described as targeting **Network 1**, a proprietary and not further disclosed target or pathway associated with SMA-related skeletal muscle and neuromuscular junction biology. Publicly available information does not specify a precise molecular target, binding mode, or pharmacologic mechanism beyond modulation of this internal Network 1 program, and no clinical-stage development or commercial branding has been disclosed.

Other names

Myocea Network 1 small moleculeNetwork 1 small moleculeNetwork1 small moleculeNetwork-1 small molecule